Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases
Lindsey R. Baden(Brigham and Women's Hospital), Jacqueline M. Miller(Moderna Therapeutics (United States)), Susanne Doblecki‐Lewis(University of Maryland, Baltimore), Avika Dixit(Boston Children's Hospital), Hana M. El Sahly(Baylor College of Medicine), Cynthia Strout, Verónica Urdaneta(Moderna Therapeutics (United States)), Joanne E. Tomassini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Frances Priddy(International AIDS Vaccine Initiative), Kathleen M. Neuzil(Center for Global Development), Dean Follmann(National Institute of Allergy and Infectious Diseases), Lawrence Corey(Fred Hutch Cancer Center), Evan J. Anderson(Emory University), Dina Stolman(Moderna Therapeutics (United States)), Gregory Hachigian(Benchmark Research (United States)), Xiaowei Wang(Argonne National Laboratory), Rituparna Das(Moderna Therapeutics (United States)), Jennifer A. Whitaker(Baylor College of Medicine), Mollie Brown(Moderna Therapeutics (United States)), J. Scott Overcash(Precision Research Institute), Weiping Deng(Yunnan Agricultural University), Brandon Essink(Velocity Clinical Research (United States)), Bethany Girard(Moderna Therapeutics (United States))
Cited by 35
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection
|New England Journal of Medicine|1990|1.3k